By Michelle Bodian, Shawn Hauser, Shane Pennington
May 11, 2023
At a DEA supply chain conference last week, Terrance Boos, Section Chief, Drug and Chemical Evaluation Section, stated that the DEA will be releasing a rule to reschedule certain hemp-derived cannabinoids.
May 11, 2023
With ketamine being the only approved psychedelic drug for medical use, ketamine clinics offer a unique opportunity for investors and entrepreneurs looking to enter the expanding market of innovative mental health therapies. In this article, we will explore the reasons behind the growing demand for ketamine clinics and the unique regulatory considerations involved in transactions involving these businesses.
By Charles Alovisetti
May 8, 2023
New York's Cannabis Control Board meets this week and a revised set of draft regulations, reflecting comments from the initial period, is expected to be released before the meeting. Attend our webinar on May 17 for a deep dive into the revised regulations.
By Andrea Golan, Ashley Davies
May 4, 2023
Arkansas Act 629 prohibits the production and sale of intoxicating substances derived from hemp. The act also amends the definition of "industrial hemp" and includes a controversial "trigger provision." Learn more about it in this Insights article.
By Sally Kent Peebles
May 3, 2023
Kentucky Governor Andy Beshears signed SB47 into law, making the Bluegrass State the 38th state to take this important step. Read this insights article for an overview of the law, including license types and qualifying medical conditions for patients.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.
